The company has to be up there as a buyout candidate. I know the market hasn't been that bullish bc of the modest efficacy compared to say BCMAs, but the unique MOA and efficacy in other cancers makes this a valuable asset IMO PS: This data was telegraphed in part by the FDA and expected IMO based on the efficacy in last line MM even though it was in combo w dex
Market Data 
Markets 
AI
